Neurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 2,262 Shares
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Haig P. Bozigian sold 2,262 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $83.10, for a total value of $187,972.20. Following the completion of the sale, the insider now directly owns 76,950 shares in the company, valued at $6,394,545. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Neurocrine Biosciences, Inc. (NBIX) traded down $1.75 during midday trading on Thursday, hitting $81.00. The stock had a trading volume of 293,474 shares, compared to its average volume of 1,022,706. The company has a market cap of $7,290.00, a PE ratio of -36.31, a price-to-earnings-growth ratio of 13.67 and a beta of 0.26. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37. Neurocrine Biosciences, Inc. has a 12-month low of $39.21 and a 12-month high of $91.82.
Several research firms recently issued reports on NBIX. BidaskClub raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Needham & Company LLC upped their price objective on Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Oppenheimer set a $95.00 price objective on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Monday, January 15th. Jefferies Group upped their price objective on Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Neurocrine Biosciences in a research report on Friday, November 3rd. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $82.31.
TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/02/08/neurocrine-biosciences-inc-nbix-insider-haig-p-bozigian-sells-2262-shares.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.